Selected press releases

In ovarian cancer, immunotherapies using checkpoint inhibitors have so far been effective in only a small number of patients. Researchers at the HI-TRON Mainz* have now discovered that lipid metabolism processes in the tumor microenvironment play a decisive role in how well such therapies work. The findings open up new avenues for using immunotherapies in a more targeted manner, increasing their effectiveness, and overcoming resistance.

Traumatic brain injuries often lead to complications with long-lasting consequences on memory, concentration and movement control. Detrimental secondary inflammatory reactions at the injured tissue sites are often responsible for this. Researchers from Ulm have now shown that a transcription factor plays a key role in reactions to TBI. When this gene regulator is activated, an elevated neuroimmune response promotes inflammation.

In the earliest phase of creating human proteins, the protein complex NAC performs an essential task by starting the first steps towards folding proteins into their correct three-dimensional structures. This discovery was made by an international research team led by scientists from the Center for Molecular Biology of Heidelberg University.

How can artificial intelligence support medical imaging diagnostics in the future and significantly improve patient care? Researchers led by Lena Maier-Hein (German Cancer Research Center, DKFZ, and NCT Heidelberg) have developed an innovative concept to address this question. The Carl Zeiss-Stiftung is funding the MEDAL* project with a total of three million euros.

Ageing is a highly individual process. An international consortium coordinated by researchers in Konstanz has developed a method that uses biomarkers to determine a person's biological age – a valuable tool for research on ageing and the development of new approaches in preventive medicine.

The results of the EPIsoDE study show that psilocybin can have a significant antidepressant effect. It is important that its use be integrated into psychotherapeutic pre- and post-treatment care.

Amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD) belong to a spectrum of neurodegenerative diseases with overlapping symptoms. Many patients have a common hallmark: A protein called TDP-43 clumps together in the neurons of the brain to form tiny lumps. Researchers at DZNE and Ulm University Hospital, together with international experts, have now discovered that these pathological changes primarily affect certain cells.

A certain blood protein regarded as an early indicator of Alzheimer’s disease also appears to play a role in other disorders. Researchers at DZNE and the Hertie Institute for Clinical Brain Research (HIH) at the University of Tübingen have found that elevated levels of phosphorylated tau protein (pTau) also occur in two lesser-known conditions that primarily affect the heart and kidneys.

Immunotherapies have greatly improved the treatment of metastatic melanoma, but they can cause serious side effects. A study led by researchers from Heidelberg University's Medical Faculty, the Heidelberg University Hospital, and the NCT in Heidelberg now shows that autoantibodies detected in the blood before the start of therapy could help to better assess the individual risk of side effects in patients.

The introduction of mammography screening programs in Europe has significantly changed breast cancer diagnoses, accompanied by a decline in breast cancer mortality rates. This is shown by the most comprehensive analyses of population-based data on breast cancer in 21 European countries to date, led by the DKFZ. The most striking finding: after the introduction of screening, significantly more early-stage, less advanced tumors were detected.

Protein activity can be precisely regulated via subtle changes in temperature using heat-sensitive switches. Underlying this capability is a novel modular design strategy developed by researchers at the Institute of Pharmacy and Molecular Biotechnology of Heidelberg University. The strategy allows the integration of sensory domains in various proteins regardless of function or spatial structure.

AI plays a huge role in the semiconductor industry, both by facilitating more efficient development processes and as a target application in development work. This is why the Fraunhofer Heilbronn Research and Innovation Centers HNFIZ are adding the Chip AI research and innovation center for AI chip design to their service range. The center is funded via the Dieter Schwarz Foundation.